Welcome to our dedicated page for Revium Recovery news (Ticker: RVRC), a resource for investors and traders seeking the latest updates and insights on Revium Recovery stock.
Revium Rx (RVRC), formerly Revium Recovery Inc., is a preclinical-stage biotechnology company that focuses on lipid-based and nanoparticle-formulated therapeutics for antimicrobial resistance and solid tumors. The news flow around Revium Rx reflects its transition into a biopharmaceutical business, its capital markets activity, and the progress of its development pipeline.
Company announcements highlight the advancement of Nano-Mupirocin, a systemic formulation of the antibiotic mupirocin designed to address severe bacterial infections caused by multidrug-resistant pathogens such as MRSA, VRE, and Ceftriaxone-Resistant Neisseria gonorrhoeae. News updates have covered regulatory steps such as the submission of a clinical trial application to the Israeli Ministry of Health and manufacturing collaborations for GMP clinical batches.
Revium Rx’s news history also includes corporate development milestones, such as the completed acquisition of LipoVation Ltd., an Israeli development-stage company specializing in lipid-based nano/micro particle medicines. This transaction marked a shift in the company’s focus toward nanoparticle-based therapeutics and drug delivery technologies. Earlier communications referenced a letter of intent to acquire LipoVac Ltd., which was associated with license and research agreements for liposomal and nano-liposomal technologies.
Investors and observers following RVRC-related news can expect coverage of pipeline updates, regulatory filings, acquisition and integration steps, and progress in its encapsulated therapeutics platform. Because the company has filed S‑1/A registration statements for an initial public offering and resale of shares, news may also address offering terms, market trading developments on OTC Markets, and risk disclosures. This page aggregates such items to provide a centralized view of material public communications related to Revium Rx and its RVRC stock.
Revium Rx (OTC: RVRC) announced progress toward a planned Phase 1 clinical trial of Nano-Mupirocin, a systemic nano-liposomal formulation of mupirocin designed to treat multidrug-resistant infections.
Key milestones: the company submitted a clinical trial application to the Israeli Ministry of Health on Oct 21, 2025, and is scaling up GMP clinical batch production with WuXi AppTec, targeting final release by end of 2025 and first-in-human studies in early 2026. The release highlights target indications (MRSA, VRE, CR-gonorrhea) and cites a global AMR therapeutics market projected to exceed $12.5B by 2030.
Revium Rx (RVRC) has completed the acquisition of LipoVation , an Israeli development-stage company specializing in lipid-based nano/micro particle medicines. The acquisition positions Revium at the forefront of advanced drug delivery technologies and marks a strategic shift toward nanoparticle-based therapeutics.
The company's pipeline includes three key programs: a novel systemic antibiotic formulation, an adjuvant for cancer immunotherapies, and an innovative immunization approach. These therapeutics are built on proprietary technologies including clinically validated nanoparticles, advanced drug-loading systems, and specialized lipid-based carriers.
Following the acquisition, David Akunis has been appointed CEO, while former CEO Inna Martin has transitioned to COO and President. LipoVation's core technology was developed by Prof. Yehezkel Barenholz, inventor of Doxil, the first FDA-approved liposomal chemotherapy drug.
Revium Recovery, Inc. (OTC Pink: RVRC) has signed a non-binding letter of intent to acquire LipoVac, Ltd., a private company specializing in advanced liposomal technologies. The acquisition involves an exchange of outstanding LipoVac shares for RVRC stock, resulting in LipoVac shareholders owning 20% to 40% of RVRC post-transaction. A condition for closing is a $7 million private placement by RVRC. The merger is expected to enhance shareholder value through R&D investments and strategic acquisitions, positioning the combined entity for significant growth in the biotech sector.